Jianghulin

Professor Hu-Lin Jiang is the doctoral supervisor of China Pharmaceutical University and Distinguished Professor of Jiangsu province, which is supported by the Outstanding Youth Fund of Jiangsu Province of China. He obtained his B.S. degree from Yanbian University in 2002, M.S. (2004) and Ph.D. (2008) degree in Seoul National University, Korea. After completing postdoctoral training at Seoul National University from 2008 to 2009, he was appointed as a research professor in Seoul National University until 2012 and now works as a professor at department of pharmaceutics, China Pharmaceutical University, China. The research interests of Jiang’s group mainly focus on the development of high tech formulations, new dosage forms, small molecule drugs and biopharmaceuticals. Besides, he has made outstanding achievements in the fields of the drug, gene and cell delivery system. As the corresponding or first author, he published 150 SCI papers in international journals including Adv Mater, Adv Funct Mater, Sci Adv, J Controlled Release, ACS Nano, Prog Polym Sci etc. with 44 H index. There are 47 patents being applied, five of which is PCT patents. And 17 patents have been authorized for invention patents, one of which has transfer to the company with twenty million RMB. He has edited 20 books and presided over 10 scientific research projects including the National Natural Science Foundation of China.

1. Bi, Y.Y.; Chen, Q.; Yang, M.Y.; Xing, L.; Jiang, H.L.* Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nat Commun. 2024; 15: 2759. (IF: 16.6)
2. Zhang, L.F.; Deng, W.Q.; Huang, Q.W.; Zhang, J.J.; Wang, Y.; Zhou, T.J.; Xing, L.; Jiang, H.L.* Vicious cycle-breaking lipid nanoparticles remodeling multicellular crosstalk to reverse liver fibrosis. Adv Mater. 2024; e2311474. (IF: 29.4)
3. Han, M.M.; Tang, L.; Huang, B.; Li, X.N.; Fang, Y.F.; Qi, L.; Duan, B.W.; Yao, Y.T.; He, Y.J.; Xing, L.; Jiang, H.L.* Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by inhibiting honeycomb cyst and alveoli interstitium remodeling. J Control Release. 2024; 366: 732-745. (IF: 10.8)
4. Duan, B.W.; Liu, Y.J.; Li, X.N.; Han, M.M.; Yu, H.Y.; Hong, H.Y.; Zhang, L.F.; Xing, L.; Jiang, H.L.* An autologous macrophage-based phenotypic transformation-collagen degradation system treating advanced liver fibrosis. Adv Sci. 2024; 11: e2306899. (IF: 15.1)
5. Sun, Y.; Xing, L.; Luo, J.; Yu, M.T.; Wang, X.J.; Wang, Y.; Zhou, T.J.; Jiang, H.L.* A pro-metastatic derivatives eliminator for in vivo dual-removal of circulating tumor cells and tumor-derived exosomes impedes their biodistribution into distant organs. Adv Sci. 2023; 10: e2304287. (IF: 15.1)
6. Han, H.; Xing, L.; Chen, B.T.; Liu, Y.; Zhou, T.J.; Wang, Y.; Zhang, L.F.; Li, L.*; Cho, C.S.*; Jiang, H.L.* Progress on the pathological tissue microenvironment barrier-modulated nanomedicine. Adv Drug Deliv Rev. 2023; 200: 115051. (IF: 16.1)
7. Han, M.M.; He, X.Y.; Tang, L.; Qi, L.; Yang, M.Y.; Wang, Y.; Xing, L.; Jeong, J.H.; Jiang, H.L.* Nanoengineered-mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice. Sci Adv. 2023; 9: eadg5358. (IF: 14.957)
8. Xing, L.; Wan, X.; Yu, M.T.; He, Y.J.; Wang, Y.; Zhou, T.J.; Liu, X.Y.; Sun, Y.; Luo, J.; Wang, W.J.; Jiang, H.L.* A novel whole blood purifier for efficient capture and separation of circulating tumor cells. Biosens Bioelectron. 2023; 232: 115292. (IF: 12.545)

1. Research Projects

(1) Ministry of Science and Technology, Government Key Special Project of National Key R&D Program, SQ2021YFE011110, Mechanism Research of Engineering Stem Cell Therapy for Asthma Treatment, 2022-01 to 2024-121 million yuan, in progress, leading

(2) National Natural Science Foundation of China, International (Regional) Cooperation and Exchange Project (Key Project), 82020108029, Mechanism Research on Regulating Pathological Barrier Normalization and Reversing Liver Fibrosis, 2021-01-01 to 2025-12-2124.8 million yuan, under research, leading

(3) National Natural Science Foundation of China, International (Regional) Cooperation and Exchange Project (Exchange Project), 81811540416, Gene Therapy for Liver Fibrosis, July 1, 2018 to June 30, 2020, 100000 yuan, completed, presided over

(4) National Natural Science Foundation of China, General Project 81773667, Rational Design and Efficacy Study of Gene Delivery System for Trinity Treatment of Leber Hereditary Optic Neuropathy, from January 1, 2018 to December 31, 2021, 670000 yuan, completed, leader

(5) Jiangsu Provincial Department of Science and Technology, Outstanding Youth Fund Project of Jiangsu Provincial Natural Science Foundation, BK20160031, Research on Precise Knockout of H-Ras Mutation in Hepatocellular Carcinoma by Intelligent Nanocarrier Nuclear Directed Delivery of Cas9 Protein Complex, RMB 1 million from July 2016 to June 2019, completed, presided over

(6) National Natural Science Foundation of China General Project, 81573369, Research on Spatiotemporal Stable and Controllable Lipoid Vesicles Targeting Hepatic Stellate Cells for Composite siRNA Therapy of Liver Fibrosis, January 2016 to December 2019, 600000 yuan, completed, leader

(7) Jiangsu Provincial Natural Science Foundation Youth Fund Project, BK20140659, pH responsive integrated dual energy carrier for targeted therapy of tumor cells, from July 2014 to June 2017, 200000 yuan, completed, presided over

(8) Jiangsu Province's Six Talent Peaks High level Talent Project, YY011, Nanogene Engineering for Targeted Therapy of Lung Cancer, from August 2014 to July 2017, 100000 yuan, completed, leader

(9) Jiangsu Province Distinguished Professor Program Project, 02410558, Research on Biocompatible Multifunctional Carriers, RMB 2012-01-2014-122 million, completed, leader

(1) First Prize of Jiangsu Medical Science and Technology Award in 2023

(2) In 2023, the second prize of the Ministry of Education's Science and Technology Progress Award

(3) In 2021, the 17th Challenge Cup National College Students' Extracurricular Academic and Technological Works Competition won the Special Set Award for Unveiling Leadership

(4) In 2021, China Pharmaceutical University Hausen Outstanding Graduate Supervisor Award

(5) In 2019, Yongning Pharmaceutical Technology Award - Outstanding Youth Award

(6) In 2018, the Youth Particle Science Award of the Chinese Particle Science Society